Compare SWBI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | CSTL |
|---|---|---|
| Founded | 1852 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 640.6M |
| IPO Year | 2000 | 2019 |
| Metric | SWBI | CSTL |
|---|---|---|
| Price | $15.63 | $22.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 953.4K | 324.1K |
| Earning Date | 06-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | $344,229,000.00 |
| Revenue This Year | $7.61 | $2.42 |
| Revenue Next Year | $3.72 | $12.69 |
| P/E Ratio | $39.32 | ★ N/A |
| Revenue Growth | ★ 10.36 | 3.66 |
| 52 Week Low | $7.73 | $14.59 |
| 52 Week High | $17.56 | $44.28 |
| Indicator | SWBI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 61.21 |
| Support Level | $13.83 | $21.94 |
| Resistance Level | N/A | $24.33 |
| Average True Range (ATR) | 0.85 | 0.81 |
| MACD | 0.17 | 0.29 |
| Stochastic Oscillator | 52.50 | 98.35 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.